Intracranial atherosclerosis;Ateromatosis intracraneal

Medicina Clinica

Volumn 131, Issue 4, 2008, Pages 141-152

  Del Saz Saucedo, Pablo ^a   Maestre Moreno, José Francisco ^a   Arenillas Lara, Juan Francisco ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Atherosclerosis; Intracraneal atherosclerosis; Intracranial stenosis; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIMITOTIC AGENT; CILOSTAZOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROMATOSIS; BRAIN ATHEROSCLEROSIS; BRAIN ISCHEMIA; DIABETES MELLITUS; DRUG ELUTING STENT; HUMAN; REVIEW; STROKE;

EID: 47049106916     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13124100     Document Type: Review

References (121)

1. Álvaro-González LC, Freijo-Guerrero MM, Sádaba-Garay F. Mecanismos inflamatorios, arteriosclerosis e ictus: datos de interés clínico y perspectivas. Rev Neurol. 2002;35:452-62.
2. Huang YN, Gao S, Li SW, Huang Y, Li JF, Wong KS, et al. Vascular lesions in Chinese patients with transient ischemic attacks. Neurology. 1997;48:524-5.
3. Wong KS, Huang YN, Gao S, Lam WWM, Chan YL, Kay R. Intracranial stenosis in Chinese patients with acute stroke. Neurology. 1998;50:812-3.
4. Sacco R, Kargman DE, Quiong G, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke. 1995;26:14-20.
5. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke. 1996;27:1974-80.
6. Inzitari D, Hachinski VC, Taylor DW, Barnett HJM. Racial differences in the anterior circulation in cerebrovascular disease. How much can be explain by risk factors? Arch Neurol. 1990;47:1080-4.
7. Mendes I, Baptista P, Soares F, Oliveira V, Ferro JM. Diabetes mellitus y estenosis intracraneales. Rev Neurol. 1999;28:1030-3.
8. Uehara T, Tabuchi M, Mori E. Risk factors for occlusive lesions of intracranial arteries in stroke-free Japanese. Eur J Neurol. 2005;12:218-22.
9. Bang OY, Lee PH, Yoon SR, Lee MA, Joo IS, Huh K. Inflammatory markers, rather than conventional risk factors, are different between carotid and MCA atherosclerosis. J Neurol Neurosurg Psychiatry. 2005;76:1128-34.
10. Suwanwela NC, Chutinetr A. Risk factors for atherosclerosis of cervicocerebral arteries: intracranial versus extracranial. Neuroepidemiology. 2003;22:37-40.
11. Arenillas JF, Álvarez-Sabín J. Basic mechanisms in intracranial largeartery atherosclerosis: advances and challenges. Cerebrovasc Dis. 2005;20 Suppl 2:75-83.
12. Segura T, Serena J, Castellanos M, Teruel J, Vilar C, Davalos A. Embolism in acute middle cerebral artery stenosis. Neurology. 2001;56:497-501.
13. The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med. 1985;313:1191-200.
14. Arenillas Lara JF. Aterosclerosis intracraneal de gran vaso: progresión y recurrencia clínica [tesis doctoral]. Barcelona: Universidad Autónoma de Barcelona; 2003 [consultado 24/02/2007]. Disponible en: http://www.tdx.cbuc.es/TESIS_UAB/AVAILABLE/TDX-1020104-120347// jfal1de1.pdf
15. Mazighi M, Tanasescu R, Ducrocq E, Vicaut E, Bracard S, Houdart E, et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology. 2006;66:1187-91.
16. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis. Outcome of patients who fail antithrombotic theraphy. Neurology. 2000;55:490-7.
17. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;353:1305-16.
18. Kang DW, Kwon SW, Yoo SH, Kwon KY, Choi CG, Kim SJ, et al. Early recurrent ischemic lesions on diffusion-weighted imaging in symptomatic intracranial atherosclerosis. Arch Neurol. 2007;64:50-4.
19. Marzewski DJ, Furlan AJ, St Louis P, Little JR, Modic MT, William G. Intracranial internal carotid artery stenosis: long term prognosis. Stroke. 1982;13:821-4.
20. Craig DR, Meguro K, Watridge C, Robertson JT, Barnett HJM, Fox AJ. Intracranial internal carotid stenosis. Stroke. 1982;13:825-8.
21. Wechsler LR, Kistler JP, Davis KR, Kaminski MJ. The prognosis of carotid siphon stenosis. Stroke 1986;17:714-8.
22. Bogousslavsky J, Barnett HJ, Fox AJ, Hachinski VC, Taylor W. Atherosclerotic disease of the middle cerebral artery. Stroke. 1986;17:1112-20.
23. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. Stroke. 1998;29:1389-92.
24. Kasner SE, Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006;113:555-63.
25. Wong KS, Li H. Long-term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atherosclerosis. Stroke. 2003;34:2361-6.
26. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445-53.
27. Rothwell PM, Warlow CP. Low risk of ischemic stroke in patients with reduced internal carotid artery lumen diameter distal to severe symptomatic carotid stenosis. Cerebral protection due to low poststenotic flow? Stroke. 2000;31:622-30.
28. Gao S, Wong KS, Hansberg T, Lam WWM, Droste DW Ringelstein EB. Microembolic signal predicts recurrent cerebral ischemic events in acute stroke patients with middle cerebral artery stenosis. Stroke. 2004;35:2832-6.
29. Wong KS, Gao S, Chan YL, Hansberg T, Lam WW, Droste DW, et al. Mechanisms of acute cerebral infarctions in patients with middle cerebral artery stenosis: a diffusion-weighted imaging and microemboli monitoring study. Ann Neurol. 2002;52:74-81.
30. Sliwka U, Klötzsch C, Popescu O, Brandt K, Schmidt P, Berli P, et al. Do chronic middle cerebral artery stenosis represent an embolic focus? A multirange transcranial Doppler study. Stroke. 1997;28:1324-7.
31. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005;111:2233-40.
32. Esagunde RU, Wong KS, Lee MP, Gan HY, Wong MC, Chang HM, et al. Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases. Cerebrovasc Dis. 2006;21:242-6.
33. Wong KS. Is the measurement of cerebral microembolic signals a good surrogate marker for evaluating the efficacy of antiplatelet agents in the prevention of stroke. Eur Neurol. 2005;53:132-9.
34. Sloan MA, Alexandrov AV, Tegeler CH, Spencer MP, Caplan LR, Feldmann E, et al. Assessment: transcranial doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommitte of the American Academy of Neurology. Neurology. 2004;62:1468-81.
35. Asil T, Balci K, Uzunca I, Kerimoglu M, Utku U. Six-month follow-up study in patients with symptomatic intracranial arterial stenosis. J Clin Neurosci. 2006;13:913-6.
36. Kern R, Steinke W, Daffertshofer M, Prager R, Hennerici M. Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease. Neurology. 2005;65:859-64.
37. Takahashi W, Ohnuki T, Ide M, Takagi S, Shinohara Y. Stroke risk of asymptomatic intra- and extracranial large-artery disease in apparently healthy adults. Cerebrovasc Dis. 2006;22:263-70.
38. Arenillas JF, Molina CA, Montaner J, Abilleira S, González- Sánchez MA, Álvarez-Sabín J. Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study. Stroke. 2001;32:2898-904.
39. Jeon HW, Cha JK. Factor related to progression of middle cerebral artery stenosis determined by transcranial Doppler ultrasonography. J Thromb Thrombolysis. 2008;25:265-9.
40. Wong KS, Li H, Lam WWM, Chan YL, Kay R. Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke. Stroke. 2002;33:532-6.
41. Ecker RD, Levy EI, Sauvageau E, Hanel RA, Hopkins LN. Current concepts in the management of intracranial atherosclerotic disease. Neurosurgery. 2006;59 5 Suppl 3:210-8.
42. Schumacher HC, Khaw AV, Meyers PM, Gupta R, Higashida RT. Intracraneal angioplasty and stent placement for cerebral atherosclerosis. J Vasc Interv Radiol. 2004;15:S123-S32.
43. Haubrich C, Kruska W, Diehl RR, Möller-Hartmann W, Klötzsch C. Dynamic autorregulation testing in patients with middle cerebral artery stenosis. Stroke. 2003;34:1881-5.
44. Uzunca I, Asil T, Balci K, Utku U. Evaluation of vasomotor reactivity by transcranial doppler sonography in patients with acute stroke who have symptomatic intracraneal and extracranial stenosis. J Ultrasound Med. 2007;26:179-85.
45. Kuroda S, Houkin K, Kamiyama H, Mitsumori K, Iwasaki Y, Abe H. Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion. Can acetazolamide test predict it? Stroke. 2001;32:2110-6.
46. Herzig R, Hlustik P, Urbanek K, Vaverka M, Burval S, Machac J, et al. Can we identify patients with carotid occlusion who would benefit from EC/IC bypass? [revisión]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004;148:119-22.
47. Lu J, Li K, Zhang M, Jiao L. Dynamic susceptibility contrast perfusion magnetic resonance imaging in patients with symptomatic unilateral middle cerebral artery stenosis or occlusion. Acta Radiol. 2007;48:335-40.
48. Derdeyn CP, Videen TO, Yundt KD, Fritsch SM, Carpenter DA, Grubb RL, et al. Variability of cerebral blood volume and oxygen extraction: stages of cerebral haemodynamic impairment revisited. Brain. 2002;125:595-607.
49. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999;340:115-26.
50. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43.
51. Ogata J, Masuda J, Yutani C, Yamaguchi T. Mechanisms of cerebral artery thrombosis: a histopathological analysis on eight necropsy cases. J Neurol Neurosurg Psychiatry. 1994;57:17-21.
52. Lee DK, Kim JS, Kwon SU, Yoo SH, Kang DW. Lesion patterns and stroke mechanism in atherosclerotic middle cerebral artery disease early diffusion-weighted imaging study. Stroke. 2005;36:2583-8.
53. Arenillas JF, Álvarez-Sabín J, Molina CA, Chacón P, Montaner J, Rovira A, et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke. 2003,34:2463-8.
54. Rosell-Novel A, Montaner J, Álvarez-Sabín J. Implicación de la angiogénesis en la isquemia cerebral humana. Rev Neurol. 2004;38: 1076-82.
55. Arenillas JF, Álvarez-Sabín J, Montaner J, Rosell A, Molina CA, Rovira A, et al. Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke. 2005;36:92-7.
56. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301-3.
57. Arenillas JF, Molina CA, Chacón P, Rovira A, Montaner J, Coscojuela E, et al. High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology. 2004;63:27-32.
58. Pedro-Botet J, Senti M, Noques X, Rubies-Prat J, Roquer J, D'Olhaberriaque L, et al. Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism. Stroke. 1992;23:1556-62.
59. Wilson PW. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am. 2004;33:467-81.
60. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812-9.
61. Bang OY, Kim JW, Lee JH, Lee MA, Lee PH, Joo IS, et al. Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology. 2005;65:296-8.
62. Obviagele B, Saver JL, Lynn MJ, Chimowitz M, for the WASID Study Group. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology. 2006;66:1344-9.
63. Park JH, Kwon HM, Roh JK. Metabolic syndrome is more associated with intracranial atherosclerosis tran extracranial atherosclerosis. Eur J Neurol. 2007;14:379-86.
64. Bang OY, Saver JL, Ovbiagele B, Choi YJ, Yoon SR, Lee KH. Adiponectin levels in patients with intracranial atherosclerosis. Neurology. 2007;68:1931-7.
65. Williams JE, Chimowitz MI, Cotsonis GA, Lynn MJ, Waddy SP. Gender differences in outcomes among patients with symptomatic intracranial arterial stenosis. Stroke. 2007;38:2055-62.
66. Millikan CK, Siekert RG, Shick RM. Studies in cerebrovascular disease: III. The use of anticoagulant drugs in the treatment of insufficiency or thrombosis within the basilar arterial system. Mayo Clin Proc. 1955;30:116-26.
67. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology. 1995;45:1488-93.
68. Koroshetz WJ. Warfarin, aspirin, and intracranial vascular disease. N Engl J Med. 2005;352:1368-70.
69. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36:782-6.
70. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59.
71. Higashida RT, Meyers PM, Connors JJ, Sacks D, Strother CM, Barr JD, et al. Intracranial angioplasty & stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. J Vasc Interv Radiol. 2005;16:1281-5.
72. Cruz-Flores S, Diamond AL. Angioplastia para la estenosis de la arteria intracraneal (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus. 2006(4). Oxford: Update Software Ltd. Disponible en: http://www.update- software.com
73. Wojak JC, Dunlap DC, Hargrave KR, DeAlvare LA, Culbertson HS, Connors JJ III. Intracranial angioplasty and stenting: long-term results from a single center. AJNR Am J Neuroradiol. 2006;27:1882-92.
74. Mori T, Mori K, Fukuoka M, Arisawa M, Honda S. Percutaneous transluminal cerebral angioplasty: serial angiographic follow-up after successful dilatation. Neuroradiology. 1997;39:111-6.
75. Henkes H, Miloslavski E, Lowens S, Reinartz J, Liebig T, Kühne D. Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (WingSpan). Neuroradiology. 2005;47:222-8.
76. Gupta R, Al-Ali F, Thomas AJ, Horowitz MB, Barrow T, Vora NA, et al. Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke. 2006;37:2562-6.
77. Lee TH, Kim DH, Lee BH, Kim HJ, Choi CH, Park KP, et al. Preliminary results of endovascular stent-assisted angioplasty for symptomatic middle cerebral artery stenosis. AJNR Am J Neuroradiol. 2005;26:166-74.
78. Kessler IM, Mounayer C, Piotin M, Spelle l, Vanzin JR, Moret J. The use of balloon-expandable stents in the management of intracranial arterial diseases: a 5-year single-center experience. AJNR Am J Neuroradiol. 2005;26:2342-8.
79. Marks MP, Wojak JC, Al-Ali F, Jayaraman M, Marcellus ML, Connors JJ, et al. Angioplasty for symptomatic intracranial stenosis: clinical outcome. Stroke. 2006;37:1016-20.
80. Marks MP, Marcellus ML, Do HM, Schraedley-Desmond PK, Steinberg GK, Tong DC, et al. Intracranial angioplasty without stenting for symptomatic atherosclerotic stenosis: long-term follow-up. AJNR Am J Neuroradiol. 2005;26:525-30.
81. Suh DC, Kim SJ, Lee DH, Kim W, Choi CG, Lee JH, et al. Outcome of endovascular treatment in symptomatic intracranial vascular stenosis. Korean J Radiol. 2005;6:1-7.
82. Blankenship JC, Krucoff MW, Werns SW, Anderson HV, Landau C, White HJ, et al. Comparison of slow oscillating versus fast balloon inflation strategies for coronary angioplasty. Am J Cardiol. 1999;83:675-80.
83. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation. 1999;99:2364-6.
84. Jiang WJ, Xu XT, Du B, Dong KH, Jin M, Wang QH, et al. Long-term outcome of elective stenting for symptomatic intracranial vertebrobasilar stenosis. Neurology. 2007;68:856-8.
85. Jiang WJ, Srivastava T, Gao F, Du B, Dong KH, Xu XT. Perforator stroke after elective stenting of symptomatic intracranial stenosis. Neurology. 2006;66:1868-72.
86. Bose A, Hartmann M, Henkes H, Liu HM, Teng MMH, Szikora I, et al. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses. The Wingspan study. Stroke. 2007;38:1531-7.
87. Hartmann M, Bose A, Henkes H, Sit S, for the Wingspan Investigador. One year stroke risks in high grade, symptomatic, medically refractory intracraneal atherosclerosis alter angioplasty and stenting: The Wingspan Trial. Actas de International Stroke Conference; 2006, febrero 16-18; Kissimmee, Florida. Kissimmee: American Stroke Association; 2006.
88. Terada T, Tsuura M, Matsumoto H, Masuo O, Tsumoto T, Yamaga H, et al. Hemorrhagic complications after endovascular therapy for atherosclerotic intracranial arterial stenoses. Neurosurgery. 2006;59:310-8.
89. Meyers PM, Higashida RT, Phatouros CC, Malek AM, Lempert TE, Dowd CF, et al. Cerebral hyperperfusion syndrome after percutaneous transluminal stenting of the craniocervical arteries. Neurosurgery. 2000;47:335-43.
90. Jiang WJ, Du B, Leung TH, Xu XT, Jin M, Dong KH. Symptomatic intracranial stenosis: cerebrovascular complications from elective stent placement. Radiology. 2007;243:188-97.
91. Rezende MT, Spelle L, Mounayer C, Piotin M, Abud DG, Moret J. Hyperperfusion syndrome after stenting for intracranial vertebral stenosis. Stroke. 2006;37:12-4.
92. Dalman JE, Beenakers IC, Moll FL, Leusink JA, Ackerstaff RG. Transcranial Doppler monitoring during carotid endarterectomy helps to identify patients at risk of postoperative hyperperfusion. Eur J Vasc Endovasc Surg. 1999;18:222-7.
93. Jiang WJ, Xu XT, Du B, Dong KH, Jin M, Wang QH, et al. Comparison of elective stenting of severe vs moderate intracranial atherosclerotic stenosis. Neurology. 2007;68:420-6.
94. Abou-Chebl A, Krieger DW, Bajzer CT, Yadav JS. Intracranial angioplasty and stenting in the awake patient. J Neuroimaging. 2006;16:216-23.
95. Lylyk P, Vila JF, Miranda C, Ferrario A, Musacchio A, Rufenacht D, Cohen JE. Endovascular reconstruction by means of stent placement in symptomatic intracranial atherosclerotic stenosis. Neurol Res. 2005;27 Suppl 1:84-8.
96. Yoon W, Seo JJ, Cho KH, Kim MK, Kim BC, Park MS, et al. Symptomatic middle cerebral artery stenosis treated with intracranial angioplasty experience in 32 patients. Radiology. 2005;237:620-6.
97. The SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke. 2004;35:1388-92.
98. Turk AS, Ahmed A, Niemann DB, Aagaard-Kienitz B, Brooks N, Levine RL. Utilization of self-expanding stents in the treatment of intracranial atherosclerotic disease in the distal small cerebral vessels. Neuroradiology. 2007;49:659-63.
99. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al for the Clopidogrel in Unstable angina to prevent Recurrents Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-33.
100. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, et al for the Clopidogrel for the Reduction of Events During Observation (CREDO) Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20.
101. Abou-Chebl A, Bashir Q, Yadav JS. Drug-eluting stents for the treatment of intracranial atherosclerosis: initial experience and midterm angiographic follow-up. Stroke. 2005;36:165-8.
102. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al; for the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-7.
103. Connors JJ III, Wojak JC. Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: evolution of technique and short-term results. J Neurosurg. 1999;91:415-23.
104. Levy EI, Hanel RA, Bendok BR, Boulos AS, Hartney ML, Guterman LR, et al. Staged stent-assisted angioplasty for symptomatic intracranial vertebrobasilar artery stenosis. J Neurosurg. 2002;97:1294-301.
105. Velat GJ, Burry MV, Eskioglu E, Dettorre RR, Firment CS, Mericle RA. The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures. Surg Neurol. 2006;65:352-8.
106. Tong FC, Cloft HJ, Joseph GJ, Samuels OB, Dion JE. Abciximab rescue in acute carotid stent thrombosis. AJNR Am J Neuroradiol. 2000;21:1750-2.
107. Qureshi AI, Saad M, Zaidat OO, Suárez JI, Alexander MJ, Fareed M, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 2002;33:1916-9.
108. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al; for the SIRUS investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23.
109. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al; for the RAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31.
110. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabaté M. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-9.
111. Moreno R. Stents recubiertos y otros dispositivos antirreestenosis. Rev Esp Cardiol. 2005;58:842-62.
112. Steinfort B, Ng PP, Faulder K, Harrington T, Grinell V, Sorby W, et al. Midterm outcomes of paclitaxel.eluting stents for the treatment of intracranial posterior circulation stenoses. J Neurosurg. 2007;106:222-5.
113. Qureshi AI, Kirmani JF, Hussein HM, Harris-Lane P, Divani AA, Suri MF, et al. Early and intermediate-term outcomes with drug-eluting stents in high-risk patients with symptomatic intracranial stenosis. Neurosurgery. 2006;59:1044-51.
114. Levy EI, Howington JU, Engh JA, Hanel RA, Levy N, Kim SH, et al. Submaximal angioplasty and staged stenting for severe posterior circulation intracranial stenosis: a technique in evolution. Neurocritic Care. 2005;2:189-97.
115. Wehman JC, Holmes DR Jr, Hanel RA, Levy EI, Hopkins LN. Intravascular ultrasound for intracranial angioplasty and stent placement: technical case report. Neurosurgery. 2006;59 4 Suppl 2:481-3.
116. Awad I, Furlan AJ, Little JR. Changes in intracranial stenotic lesions after extracranial-intracranial bypass surgery. J Neurosurg. 1984;60:771-6.
117. Gumerlock MK, Ono H, Neuwelt EA. Can a patent extracranial-intracranial bypass provoke the conversion of an intracranial arterial stenosis to a symptomatic occlusion? Neurosurgery. 1983;12:391-400.
118. Higashida RT, Meyers PM. Intracranial angioplasty and stenting for cerebral atherosclerosis: new treatments for stroke are needed! Neuroradiology. 2006;48:367-72.
119. Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, Lindner JR. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007;116:276-84.
120. Klein IF, Lavallée PC, Touboul PJ, Schouman-Claeys E, Amarenco P. In vivo middle cerebral artery plaque imaging by high-resolution MRI. Neurology. 2006;67:327-9.
121. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, et al. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (Berl). 2007;113:13-21.